Suppr超能文献

新型PDEδ自噬降解剂的发现:以自噬连接化合物(ATTEC)为例的研究

Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC).

作者信息

Bao Jingying, Chen Zhenqian, Li Yu, Chen Long, Wang Wei, Sheng Chunquan, Dong Guoqiang

机构信息

School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.

School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China.

出版信息

ACS Med Chem Lett. 2023 Dec 29;15(1):29-35. doi: 10.1021/acsmedchemlett.3c00161. eCollection 2024 Jan 11.

Abstract

The autophagy-tethering compound (ATTEC) technology has emerged as a promising strategy for targeted protein degradation (TPD). Here, we report the discovery of the first generation of PDEδ autophagic degraders using an ATTEC approach. The most promising compound exhibited potent PDEδ binding affinity and efficiently induced PDEδ degradation in a concentration-dependent manner. Mechanistic studies confirmed that compound reduced the PDEδ protein level through lysosome-mediated autophagy without affecting the PDEδ mRNA expression. Importantly, compound was much more effective in suppressing the growth in KRAS mutant pancreatic cancer cells than the corresponding PDEδ inhibitor. Taken together, this study expands the application scope of the ATTEC approach and highlights the effectiveness of the PDEδ autophagic degradation strategy in antitumor drug discovery.

摘要

自噬栓系化合物(ATTEC)技术已成为一种有前景的靶向蛋白质降解(TPD)策略。在此,我们报告了使用ATTEC方法发现的第一代PDEδ自噬降解剂。最有前景的化合物表现出强大的PDEδ结合亲和力,并以浓度依赖性方式有效诱导PDEδ降解。机制研究证实,该化合物通过溶酶体介导的自噬降低了PDEδ蛋白水平,而不影响PDEδ mRNA表达。重要的是,该化合物在抑制KRAS突变型胰腺癌细胞生长方面比相应的PDEδ抑制剂更有效。综上所述,本研究扩展了ATTEC方法的应用范围,并突出了PDEδ自噬降解策略在抗肿瘤药物发现中的有效性。

相似文献

1
Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC).
ACS Med Chem Lett. 2023 Dec 29;15(1):29-35. doi: 10.1021/acsmedchemlett.3c00161. eCollection 2024 Jan 11.
2
Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells.
ACS Med Chem Lett. 2022 Jan 12;13(2):298-303. doi: 10.1021/acsmedchemlett.1c00670. eCollection 2022 Feb 10.
3
Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
J Med Chem. 2020 Jul 23;63(14):7892-7905. doi: 10.1021/acs.jmedchem.0c00929. Epub 2020 Jul 14.
5
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research.
J Med Chem. 2023 Feb 9;66(3):1700-1711. doi: 10.1021/acs.jmedchem.2c01712. Epub 2023 Jan 30.
6
Targeting lipid droplets for autophagic degradation by ATTEC.
Autophagy. 2021 Dec;17(12):4486-4488. doi: 10.1080/15548627.2021.1967616. Epub 2021 Aug 26.
7
Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells.
J Med Chem. 2025 May 8;68(9):9241-9259. doi: 10.1021/acs.jmedchem.4c02636. Epub 2025 Apr 27.
8
Manipulating autophagic degradation in human diseases: from mechanisms to interventions.
Life Med. 2022 Oct 11;1(2):120-148. doi: 10.1093/lifemedi/lnac043. eCollection 2022 Oct.
10
Bioorthogonal Aptamer-ATTEC Conjugates for Degradation of Alpha-Synuclein via Autophagy-Lysosomal Pathway.
Small. 2024 Feb;20(8):e2306760. doi: 10.1002/smll.202306760. Epub 2023 Oct 11.

引用本文的文献

1
Targeted protein degradation with small molecules for cancer immunotherapy.
Asian J Pharm Sci. 2025 Aug;20(4):101058. doi: 10.1016/j.ajps.2025.101058. Epub 2025 Apr 22.
2
Targeted Degradation Technologies Utilizing Autophagy.
Int J Mol Sci. 2025 Jul 8;26(14):6576. doi: 10.3390/ijms26146576.
3
Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains.
ACS Pharmacol Transl Sci. 2025 Mar 14;8(4):978-1012. doi: 10.1021/acsptsci.4c00726. eCollection 2025 Apr 11.
4
R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation.
Autophagy. 2025 Sep;21(9):1945-1961. doi: 10.1080/15548627.2025.2483886. Epub 2025 Apr 4.
5
Exploring Arylidene-Indolinone Ligands of Autophagy Proteins LC3B and GABARAP.
ACS Med Chem Lett. 2025 Jan 6;16(2):271-277. doi: 10.1021/acsmedchemlett.4c00517. eCollection 2025 Feb 13.
7
Exploring Arylidene-Indolinone Ligands of Autophagy Proteins LC3B and GABARAP.
bioRxiv. 2024 Oct 29:2024.02.25.581879. doi: 10.1101/2024.02.25.581879.
8
Targeted protein degradation: advances in drug discovery and clinical practice.
Signal Transduct Target Ther. 2024 Nov 6;9(1):308. doi: 10.1038/s41392-024-02004-x.
9
Methylarginine targeting chimeras for lysosomal degradation of intracellular proteins.
Nat Chem Biol. 2024 Dec;20(12):1566-1576. doi: 10.1038/s41589-024-01741-y. Epub 2024 Oct 16.

本文引用的文献

1
Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype.
Nat Commun. 2023 Nov 30;14(1):7908. doi: 10.1038/s41467-023-43657-6.
2
Emerging degrader technologies engaging lysosomal pathways.
Chem Soc Rev. 2022 Oct 31;51(21):8832-8876. doi: 10.1039/d2cs00624c.
3
PROTACs: past, present and future.
Chem Soc Rev. 2022 Jun 20;51(12):5214-5236. doi: 10.1039/d2cs00193d.
6
Discovery of novel KRAS‒PDE inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models.
Acta Pharm Sin B. 2022 Jan;12(1):274-290. doi: 10.1016/j.apsb.2021.07.009. Epub 2021 Jul 19.
7
Strategies for designing proteolysis targeting chimaeras (PROTACs).
Med Res Rev. 2022 May;42(3):1280-1342. doi: 10.1002/med.21877. Epub 2022 Jan 10.
8
Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy.
Chem Commun (Camb). 2021 Dec 7;57(97):13194-13197. doi: 10.1039/d1cc04661f.
9
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery.
J Med Chem. 2021 Aug 12;64(15):10606-10620. doi: 10.1021/acs.jmedchem.1c00895. Epub 2021 Jul 28.
10
Machinery, regulation and pathophysiological implications of autophagosome maturation.
Nat Rev Mol Cell Biol. 2021 Nov;22(11):733-750. doi: 10.1038/s41580-021-00392-4. Epub 2021 Jul 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验